Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.

Details

Language :

English

ISSN :

13665278

Volume :

28

Issue :

3-7

Database :

Complementary Index

Journal :

Health Technology Assessment

Publication Type :

Academic Journal

Accession number :

175180521

Full Text :

https://doi.org/10.3310/LEXB9006